Table 5.

Summary of prospective studies of SBRT for early-stage lung cancer, along with the current study.

Article	Patients	Stage	Dose	Follow-up	LC	OS	Toxicity
Hoyer et al. [18]	40	Stage I	45 Gy in 3 fractions	29 months	2-year, 85%	2-year, 47%	Grade ≥ 2, 48%
Fakiris et al. [19]	70	T1-T2	60–66 Gy in 3 fractions	50 months	3-year, 88.1%	3-year, 42.7%	Grade ≥ 3, 15.7%
Baumann et al. [20]	57	T1-T2	45 Gy in 3 fractions	35 months	3-year, 92%	3-year, 60%	Grade ≥ 3, 28%
Timmerman et al. [21]	55	T1-T2	54 Gy in 3 fractions	34 months	3-year, 91%	3-year, 56%	Grade ≥ 3, 16%
Timmerman et al. [22]	33	T1-T2	54 Gy in 3 fractions	48.1 months	4-year, 96%	4-year, 57%	Grade ≥ 3, 8%
Nagata et al. [23]	100 (inoperable)	T1	48 Gy in 4 fractions	47 months	3-year, 87.3%	3-year, 59.9%	Grade ≥ 3, 12.5%
	64 (operable)	T1	48 Gy in 4 fractions	67 months	3-year, 85.4%	3-year, 76.5%	Grade ≥ 3, 6.2%
Videtic et al. [24]	39	T1-T2	34 Gy in 1 fraction	3.5 years	5-year, 89.4%	5-year, 29.6%	Grade ≥ 3, 2.6%
	45	T1-T2	48 Gy in 4 fractions	4.0 years	5-year, 93.2%	5-year, 41.1%	Grade ≥ 3, 11.1%
Current study	168 (Photon)	T1-T2	60 Gy in 4 fractions	2.7 years	5-year, 90.8%	5-year. 51.7%	Grade ≥ 3, 16.7%
	34 (Proton)	T1-T2	60 Gy in 4 fractions	2.2 years	5-year, 83.6%	5-year, 51.9%	Grade ≥ 3, 17.6%

SBRT, stereotactic body radiation therapy; LC, local control; OS, overall survival.